Chemistry:5-MeO-DiBF

From HandWiki

5-MeO-DiBF, also known as 5-methoxy-N,N-diisopropyl-3-(2-aminoethyl)benzofuran or as 1-oxa-5-MeO-DiPT, is a psychedelic drug of the benzofuran family related to the psychedelic tryptamine 5-MeO-DiPT.[1][2][3] It is the analogue and bioisostere of 5-MeO-DiPT in which the indole nitrogen has been replaced with an oxygen atom, making it a benzofuran rather than tryptamine.[1] The drug has been sold online as a novel designer drug starting in 2015.[2][4]

Use and effects

The dose of 5-MeO-DiBF has been given as 10 to 40 mg orally, with a light dose being 10 mg, a common dose being 20 mg, and a strong dose being 40 mg.[2] Its onset is said to be 45 minutes and its duration is variably said to be 4 to 9 hours.[2] In addition to oral administration, the drug may also be insufflated.[2] The effects of 5-MeO-DiBF have been reported to include psychedelic head space, tactile sensations and tingling, and increased sexual desire, among others.[2]

Interactions

Pharmacology

Pharmacodynamics

Analogues of 5-MeO-DiBF have been found to interact with serotonin receptors including the serotonin 5-HT1A and 5-HT2 receptors.[5][6]

Chemistry

Analogues

Analogues of 5-MeO-DiBF include the benzofurans dimemebfe (5-MeO-BFE), MiPBF (1-oxa-MiPT), 3-APB (1-oxa-AMT), and mebfap (5-MeO-3-APB; 1-oxa-5-MeO-AMT) and the tryptamine 5-MeO-DiPT, among others.[3][1]

History

5-MeO-DiBF has been sold online as a designer drug and was first definitively identified in December 2015 by a forensic laboratory in Slovenia.[2][4]

Society and culture

International

Armenia

The drug is a controlled substance in Armenia as of 2022.[7]

Canada

5-MeO-DiBF is not a controlled substance in Canada as of 2025.[8]

United States

5-MeO-DiBF is not an explicitly controlled substance in the United States.[9] However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.

See also

References

  1. ↑ 1.0 1.1 1.2 "New Psychoactive Substances: Major Groups, Laboratory Testing Challenges, Public Health Concerns, and Community-Based Solutions". Journal of Chemistry 2023: 1–36. 2 February 2023. doi:10.1155/2023/5852315. ISSN 2090-9071. 
  2. ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 "5-MeO-DiBF". The Drug Users Bible: Harm Reduction, Risk Mitigation, Personal Safety. MxZero Publishing. 9 April 2019. ISBN 978-0-9955936-8-8. https://drugusersbible.org/content/chemscape/psychedelics/5-meo-dibf/. 
  3. ↑ 3.0 3.1 "The Characterization of 2-(5-Methoxy-1-benzofuran-3-yl)-N,N-dimethylethanamine (5-MeO-BFE) and Differentiation from its N-Ethyl Analog". Microgram Journal 9 (1): 39–45. 2012. http://www.dea.gov/pr/microgram-journals/2012/mj9-1_39-45.pdf. 
  4. ↑ 4.0 4.1 "Europol 2015 Annual Report on the implementation of Council Decision 2005/387/JHA". European Monitoring Center for Drugs and Drug Addiction. http://www.emcdda.europa.eu/system/files/publications/2880/TDAS16001ENN.pdf. 
  5. ↑ "Benzofuran bioisosteres of hallucinogenic tryptamines". Journal of Medicinal Chemistry 35 (11): 2061–2064. May 1992. doi:10.1021/jm00089a017. PMID 1534585. 
  6. ↑ "Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes". Neuropharmacology 29 (3): 193–198. March 1990. doi:10.1016/0028-3908(90)90001-8. PMID 2139186. 
  7. ↑ "5-MeO-DIBF" (in ru). https://aipsin.com/newsubstance/887/. 
  8. ↑ "Controlled Drugs and Substances Act". https://laws-lois.justice.gc.ca/eng/acts/c-38.8/FullText.html. 
  9. ↑ Orange Book: List of Controlled Substances and Regulated Chemicals (January 2026), United States: U.S. Department of Justice: Drug Enforcement Administration (DEA): Diversion Control Division, January 2026, https://www.deadiversion.usdoj.gov/schedules/orangebook/orangebook.pdf 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:5-MeO-DiBF&oldid=4244949"